Gary Shapiro

Title: Gary Shapiro: Innovator in Chimeric Receptor Technology

Introduction

Gary Shapiro is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of chimeric receptors that target specific proteins involved in cancer treatment.

Latest Patents

Gary Shapiro holds a patent for "Chimeric receptors targeting ADGRE2 and/or CLEC12A and uses thereof." This patent describes innovative chimeric receptors that specifically target ADGRE2 and CLEC12A. The disclosed subject matter includes cells that comprise these targeted chimeric receptors, which can be utilized for treating tumors, such as acute myeloid leukemia (AML).

Career Highlights

Throughout his career, Gary has worked with esteemed institutions, including Memorial Sloan Kettering Cancer Center and the Sloan Kettering Institute for Cancer Research. His work has focused on advancing cancer therapies through innovative receptor technologies.

Collaborations

Gary has collaborated with notable professionals in the field, including Michel Sadelain and Sascha P. Haubner. These collaborations have furthered research and development in cancer treatment methodologies.

Conclusion

Gary Shapiro's contributions to chimeric receptor technology represent a significant advancement in the fight against cancer. His innovative work continues to inspire future research and development in the field.